Want to find your lens? Five questions, no jargon — they tell you which of four reads fits how you already think.
A wonderful business — priced for growth it hasn't delivered.
A great company, but no margin of safety at this price. Worth watching, not worth buying here.
The five checks
3 good · 1 caution · 1 warning
- WarningOvervaluedFair value ~$69 vs $94 — trading 27% above what the math supports.
- GoodPrice is in line with its recordPriced for ~9%/yr, roughly what it has delivered (32.9%/yr) — from a depressed FY22 base.
- GoodRevenue still growingUp 5.5% last year — demand isn't the problem.
- GoodCash flow compoundingFree cash flow up ~32.9%/yr — the engine is growing.
- CautionManageable net debtNet debt of $1B — about 0.6× annual free cash flow. Normal for a mature company.
Price against fair value
What today's price assumes
Hold the price fixed and work backwards: how fast would free cash flow have to grow for $94 to make sense?
Price is in line with its record.
How fair value is calculated
No analyst forecasts, no black box, no AI. Six lines from the filing to the answer.
- Free cash flow, FY25Operating cash flow less capital spending, from the annual report$0.91B
- Ten years of it, growing 5% a year, each counted 9% lessThe same growth and discount for every company$7.45B
- Everything after year tenGrowing 2.5% a year, counted the same way+ $9.88B
- The business, in today's money$17.33B
- Subtract net debtBorrowings and finance leases less cash and securities− $0.59B
- Divide by the shares on file÷ 0.244B
Fair value per share$69
If our assumptions are wrong
Fair value per share under a faster or slower decade, and a gentler or harsher discount. The corners are where the $50 to $96 range comes from.
| 3% growth | 5% growth | 7% growth | |
|---|---|---|---|
| 8% discount | $70 | $82 | $96 |
| 9% discount | $59 | $69 | $80 |
| 10% discount | $50 | $59 | $68 |
The blue cell is the published method. Some cells sit above today’s price, some below.
Free cash flow, ten years
$ billions · Form 10-K
What the math is really telling you. Watch whether cash flow is compounding — that, more than any single year, is what a value read hangs on.
How this was built. Every figure is computed from Xylem Inc.'s SEC filings — no estimates, no AI. Two-stage DCF: 9% discount rate, 5% free-cash-flow growth for 10 years, 2.5% terminal. Free cash flow is operating cash flow less capital spending. Net cash is cash and marketable securities less borrowings, commercial paper and finance leases; operating leases are disclosed but never counted as debt. Fundamentals are from the FY25 annual report and change only when a new one is filed. Price of $94.18 taken 2026-11-15 (Google Finance, manual entry, 2026-11-13) — it is not live and does not move during the day.
Read Xylem another way
TickerMath is an educational tool, not investment advice — it computes one model from SEC filings and can be wrong. How we compute this →